<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35327650</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2218-273X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
              <Day>16</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biomolecules</Title>
          <ISOAbbreviation>Biomolecules</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Multicenter <sup>18</sup>F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer's Disease.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">458</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/biom12030458</ELocationID>
        <Abstract>
          <AbstractText>Tau aggregates accumulate in the Alzheimer's disease (AD) brain according to the established Braak staging scheme and spread from transentorhinal over limbic regions to the neocortex. To impact the management of AD patients, an in vivo tool for tau Braak staging is needed. First-generation tau tracers have limited performance in detecting early stages of tau. Therefore, we tested the corresponding capability of the next-generation tau tracer, <sup>18</sup>F-PI-2620. We analyzed <sup>18</sup>F-PI-2620 multicenter PET data from 37 beta-amyloid-positive AD dementia patients and those from 26 healthy controls. We applied kinetic modeling of the 0-60 min p.i. PET data using MRTM2 with the lower cerebellum as the reference region to extract Braak stage-dependent distribution volume ratios, whereas controls were used to define Braak stage PET positivity thresholds. Stage-dependent PET positivity widely followed the Braak scheme (except Braak stage III) presenting descending frequency of PET positivity from Braak I (43%), II (38%), III (49%), IV (35%), V (30%) to VI (14%). A strictly hierarchical model was met by 64% of AD dementia cases. Nineteen percent showed a hippocampal sparing tauopathy pattern. Thus, we could assign 87% to the six-stage hierarchical Braak model including tauopathy variants. <sup>18</sup>F-PI-2620 PET appears to be able to perform Braak tau staging of AD in vivo.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Rullmann</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-2683-9432</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Nuclear Medicine, University of Leipzig, 04103 Leipzig, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brendel</LastName>
            <ForeName>Matthias</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 80336 Munich, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schroeter</LastName>
            <ForeName>Matthias L</ForeName>
            <Initials>ML</Initials>
            <AffiliationInfo>
              <Affiliation>Clinic for Cognitive Neurology, University of Leipzig, 04103 Leipzig, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Max Planck Institute for Human Cognitive and Brain Sciences, 04103 Leipzig, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saur</LastName>
            <ForeName>Dorothee</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Leipzig, 04103 Leipzig, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Levin</LastName>
            <ForeName>Johannes</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0001-5092-4306</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>German Center for Neurodegenerative Disorders (DZNE) Munich, 81377 Munich, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Perneczky</LastName>
            <ForeName>Robert G</ForeName>
            <Initials>RG</Initials>
            <AffiliationInfo>
              <Affiliation>Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>German Center for Neurodegenerative Disorders (DZNE) Munich, 81377 Munich, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, 80336 Munich, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Ageing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, London W6 8RP, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield S10 2HQ, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tiepolt</LastName>
            <ForeName>Solveig</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nuclear Medicine, University of Leipzig, 04103 Leipzig, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patt</LastName>
            <ForeName>Marianne</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nuclear Medicine, University of Leipzig, 04103 Leipzig, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mueller</LastName>
            <ForeName>Andre</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0001-7271-9303</Identifier>
            <AffiliationInfo>
              <Affiliation>Life Molecular Imaging GmbH, 13353 Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Villemagne</LastName>
            <ForeName>Victor L</ForeName>
            <Initials>VL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Classen</LastName>
            <ForeName>Joseph</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0001-7182-6967</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Leipzig, 04103 Leipzig, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stephens</LastName>
            <ForeName>Andrew W</ForeName>
            <Initials>AW</Initials>
            <AffiliationInfo>
              <Affiliation>Life Molecular Imaging GmbH, 13353 Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sabri</LastName>
            <ForeName>Osama</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nuclear Medicine, University of Leipzig, 04103 Leipzig, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barthel</LastName>
            <ForeName>Henryk</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nuclear Medicine, University of Leipzig, 04103 Leipzig, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>On Behalf Of The German Imaging Initiative For Tauopathies Gii T</LastName>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Biomolecules</MedlineTA>
        <NlmUniqueID>101596414</NlmUniqueID>
        <ISSNLinking>2218-273X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000710692">((18)F)PI-2620</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005462">Fluorine Radioisotopes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005462" MajorTopicYN="N">Fluorine Radioisotopes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024801" MajorTopicYN="Y">Tauopathies</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Alzheimer’s disease</Keyword>
        <Keyword MajorTopicYN="Y">Braak staging</Keyword>
        <Keyword MajorTopicYN="Y">PET</Keyword>
        <Keyword MajorTopicYN="Y">PI-2620</Keyword>
        <Keyword MajorTopicYN="Y">Tau</Keyword>
      </KeywordList>
      <CoiStatement>A.M. and A.W.S. are full-time employees of Life Molecular Imaging GmbH. M.B. received speaker honoraria from Roche, GE healthcare and LMI and is an advisor of LMI. R.G.P. received speaker honoraria, advisory fees and research support from Janssen, Biogen, Eli Lilly, Novo Nordisk, Schwabe, Bayer, Grifols and Roche. J.L. reports speaker fees from Bayer Vital, Biogen and Roche, consulting fees from Axon Neuroscience and Biogen, author fees from Thieme medical publishers and W. Kohlhammer GmbH medical publishers, non-financial support from Abbvie and compensation for duty as part-time CMO from MODAG, outside the submitted work. All other authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>25</Day>
          <Hour>1</Hour>
          <Minute>4</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35327650</ArticleId>
        <ArticleId IdType="pmc">PMC8946049</ArticleId>
        <ArticleId IdType="doi">10.3390/biom12030458</ArticleId>
        <ArticleId IdType="pii">biom12030458</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–259. doi: 10.1007/BF00308809.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00308809</ArticleId>
            <ArticleId IdType="pubmed">1759558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braak H., Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging. 1997;18:351–357. doi: 10.1016/S0197-4580(97)00056-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0197-4580(97)00056-0</ArticleId>
            <ArticleId IdType="pubmed">9330961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braak H., Alafuzoff I., Arzberger T., Kretzschmar H., Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389–404. doi: 10.1007/s00401-006-0127-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-006-0127-z</ArticleId>
            <ArticleId IdType="pmc">PMC3906709</ArticleId>
            <ArticleId IdType="pubmed">16906426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braak H., Thal D.R., Ghebremedhin E., Del Tredici K. Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 2011;70:960–969. doi: 10.1097/NEN.0b013e318232a379.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/NEN.0b013e318232a379</ArticleId>
            <ArticleId IdType="pubmed">22002422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hyman B.T., Phelps C.H., Beach T.G., Bigio E.H., Cairns N.J., Carrillo M.C., Dickson D.W., Duyckaerts C., Frosch M.P., Masliah E., et al.  National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers. Dement. 2012;8:1–13. doi: 10.1016/j.jalz.2011.10.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jalz.2011.10.007</ArticleId>
            <ArticleId IdType="pmc">PMC3266529</ArticleId>
            <ArticleId IdType="pubmed">22265587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chien D.T., Bahri S., Szardenings A.K., Walsh J.C., Mu F., Su M.-Y., Shankle W.R., Elizarov A., Kolb H.C. Early clinical PET imaging results with the novel PHF-tau radioligand F-18-T807. J. Alzheimers. Dis. 2013;34:457–468. doi: 10.3233/JAD-122059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/JAD-122059</ArticleId>
            <ArticleId IdType="pubmed">23234879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Villemagne V.L., Okamura N. In vivo tau imaging: Obstacles and progress. Alzheimers. Dement. 2014;10:S254–S264. doi: 10.1016/j.jalz.2014.04.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jalz.2014.04.013</ArticleId>
            <ArticleId IdType="pubmed">24924676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwarz A.J., Yu P., Miller B.B., Shcherbinin S., Dickson J., Navitsky M., Joshi A.D., Devous M.D., Mintun M.S. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain. 2016;139:1539–1550. doi: 10.1093/brain/aww023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/aww023</ArticleId>
            <ArticleId IdType="pubmed">26936940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herholz K. Spread of tau deposits: Can we trust in vivo findings? Brain. 2018;141:10–12. doi: 10.1093/brain/awx340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awx340</ArticleId>
            <ArticleId IdType="pubmed">29325049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soleimani-Meigooni D.N., Iaccarino L., La Joie R., Baker S., Bourakova V., Boxer A.L., Edwards L., Eser R., Gorno-Tempini M.-L., Jagust W.J., et al.  18F-flortaucipir PET to autopsy comparisons in Alzheimer’s disease and other neurodegenerative diseases. Brain. 2020;143:3477–3494. doi: 10.1093/brain/awaa276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awaa276</ArticleId>
            <ArticleId IdType="pmc">PMC7719031</ArticleId>
            <ArticleId IdType="pubmed">33141172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baker S.L., Harrison T.M., Maass A., La Joie R., Jagust W.J. Effect of Off-Target Binding on 18F-Flortaucipir Variability in Healthy Controls Across the Life Span. J. Nucl. Med. 2019;60:1444–1451. doi: 10.2967/jnumed.118.224113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2967/jnumed.118.224113</ArticleId>
            <ArticleId IdType="pmc">PMC6785795</ArticleId>
            <ArticleId IdType="pubmed">30877180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pascoal T.A., Therriault J., Benedet A.L., Savard M., Lussier F.Z., Chamoun M., Tissot C., Qureshi M.N.I., Kang M.S., Mathotaarachchi S., et al.  18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain. 2020;143:2818–2830. doi: 10.1093/brain/awaa180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awaa180</ArticleId>
            <ArticleId IdType="pubmed">32671408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kroth H., Oden F., Molette J., Schieferstein H., Capotosti F., Mueller A., Berndt M., Schmitt-Willich H., Darmency V., Gabellieri E., et al.  Discovery and preclinical characterization of 18FPI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer’s disease and other tauopathies. Eur. J. Nucl. Med. Mol. Imaging. 2019;46:2178–2189. doi: 10.1007/s00259-019-04397-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00259-019-04397-2</ArticleId>
            <ArticleId IdType="pmc">PMC6667408</ArticleId>
            <ArticleId IdType="pubmed">31264169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mueller A., Bullich S., Barret O., Madonia J., Berndt M., Papin C., Perrotin A., Koglin N., Kroth H., Pfeifer A., et al.  Tau PET imaging with 18F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study. J. Nucl. Med. 2020;61:911–919. doi: 10.2967/jnumed.119.236224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2967/jnumed.119.236224</ArticleId>
            <ArticleId IdType="pmc">PMC7262222</ArticleId>
            <ArticleId IdType="pubmed">31712323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brendel M., Barthel H., van Eimeren T., Marek K., Beyer L., Song M., Palleis C., Gehmeyr M., Fietzek U., Respondek G., et al.  Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurol. 2020;77:1408–1419. doi: 10.1001/jamaneurol.2020.2526.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2020.2526</ArticleId>
            <ArticleId IdType="pmc">PMC7341407</ArticleId>
            <ArticleId IdType="pubmed">33165511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ichise M., Liow J.-S., Lu J.-Q., Takano A., Model K., Toyama H., Suhara T., Suzuki K., Innis R.B., Carson R.E. Linearized reference tissue parametric imaging methods: Application to 11CDASB positron emission tomography studies of the serotonin transporter in human brain. J. Cereb. Blood Flow Metab. 2003;23:1096–1112. doi: 10.1097/01.WCB.0000085441.37552.CA.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.WCB.0000085441.37552.CA</ArticleId>
            <ArticleId IdType="pubmed">12973026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murray M.E., Graff-Radford N.R., Ross O.A., Petersen R.C., Duara R., Dickson D.W. Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics: A retrospective study. Lancet Neurol. 2011;10:785–796. doi: 10.1016/S1474-4422(11)70156-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(11)70156-9</ArticleId>
            <ArticleId IdType="pmc">PMC3175379</ArticleId>
            <ArticleId IdType="pubmed">21802369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mattay V.S., Fotenos A.F., Ganley C.J., Marzella L. Brain Tau Imaging: Food and Drug Administration Approval of 18F-Flortaucipir Injection. J. Nucl. Med. 2020;61:1411–1412. doi: 10.2967/jnumed.120.252254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2967/jnumed.120.252254</ArticleId>
            <ArticleId IdType="pubmed">32753388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pascoal T.A., Benedet A.L., Tudorascu D.L., Therriault J., Mathotaarachchi S., Savard M., Lussier F.Z., Tissot C., Chamoun M., Kang M.S., et al.  Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages. Brain. 2021;144:3517–3528. doi: 10.1093/brain/awab248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awab248</ArticleId>
            <ArticleId IdType="pmc">PMC8677534</ArticleId>
            <ArticleId IdType="pubmed">34515754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo J.L., Lee V.M.-Y. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J. Biol. Chem. 2011;286:15317–15331. doi: 10.1074/jbc.M110.209296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M110.209296</ArticleId>
            <ArticleId IdType="pmc">PMC3083182</ArticleId>
            <ArticleId IdType="pubmed">21372138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stancu I.-C., Vasconcelos B., Ris L., Wang P., Villers A., Peeraer E., Buist A., Terwel D., Baatsen P., Oyelami T., et al.  Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice. Acta Neuropathol. 2015;129:875–894. doi: 10.1007/s00401-015-1413-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-015-1413-4</ArticleId>
            <ArticleId IdType="pmc">PMC4436846</ArticleId>
            <ArticleId IdType="pubmed">25862635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pascoal T.A., Benedet A.L., Ashton N.J., Kang M.S., Therriault J., Chamoun M., Savard M., Lussier F.Z., Tissot C., Karikari T.K., et al.  Microglial activation and tau propagate jointly across Braak stages. Nat. Med. 2021;27:1592–1599. doi: 10.1038/s41591-021-01456-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-021-01456-w</ArticleId>
            <ArticleId IdType="pubmed">34446931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010;9:119–128. doi: 10.1016/S1474-4422(09)70299-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(09)70299-6</ArticleId>
            <ArticleId IdType="pmc">PMC2819840</ArticleId>
            <ArticleId IdType="pubmed">20083042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jack C.R., Wiste H.J., Botha H., Weigand S.D., Therneau T.M., Knopman D.S., Graff-Radford J., Jones D.T., Ferman T.J., Boeve B.F., et al.  The bivariate distribution of amyloid-β and tau: Relationship with established neurocognitive clinical syndromes. Brain. 2019;142:3230–3242. doi: 10.1093/brain/awz268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awz268</ArticleId>
            <ArticleId IdType="pmc">PMC6763736</ArticleId>
            <ArticleId IdType="pubmed">31501889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jack C.R., Bennett D.A., Blennow K., Carrillo M.C., Feldman H.H., Frisoni G.B., Hampel H., Jagust W.J., Johnson K.A., Knopman D.S., et al.  A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539–547. doi: 10.1212/WNL.0000000000002923.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000002923</ArticleId>
            <ArticleId IdType="pmc">PMC4970664</ArticleId>
            <ArticleId IdType="pubmed">27371494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crary J.F., Trojanowski J.Q., Schneider J.A., Abisambra J.F., Abner E.L., Alafuzoff I., Arnold S.E., Attems J., Beach T.G., Bigio E.H., et al.  Primary age-related tauopathy (PART): A common pathology associated with human aging. Acta Neuropathol. 2014;128:755–766. doi: 10.1007/s00401-014-1349-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-014-1349-0</ArticleId>
            <ArticleId IdType="pmc">PMC4257842</ArticleId>
            <ArticleId IdType="pubmed">25348064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jack C.R. PART and SNAP. Acta Neuropathol. 2014;128:773–776. doi: 10.1007/s00401-014-1362-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-014-1362-3</ArticleId>
            <ArticleId IdType="pmc">PMC4231211</ArticleId>
            <ArticleId IdType="pubmed">25380757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lowe V.J., Wiste H.J., Senjem M.L., Weigand S.D., Therneau T.M., Boeve B.F., Josephs K.A., Fang P., Pandey M.K., Murray M.E., et al.  Widespread brain tau and its association with ageing, Braak stage and Alzheimer’s dementia. Brain. 2018;141:271–287. doi: 10.1093/brain/awx320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awx320</ArticleId>
            <ArticleId IdType="pmc">PMC5837250</ArticleId>
            <ArticleId IdType="pubmed">29228201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schöll M., Lockhart S.N., Schonhaut D.R., O’Neil J.P., Janabi M., Ossenkoppele R., Baker S.L., Vogel J.W., Faria J., Schwimmer H.D., et al.  PET Imaging of Tau Deposition in the Aging Human Brain. Neuron. 2016;89:971–982. doi: 10.1016/j.neuron.2016.01.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2016.01.028</ArticleId>
            <ArticleId IdType="pmc">PMC4779187</ArticleId>
            <ArticleId IdType="pubmed">26938442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maass A., Lockhart S.N., Harrison T.M., Bell R.K., Mellinger T., Swinnerton K., Baker S.L., Rabinovici G.D., Jagust W.J. Entorhinal Tau Pathology, Episodic Memory Decline, and Neurodegeneration in Aging. J. Neurosci. 2018;38:530–543. doi: 10.1523/JNEUROSCI.2028-17.2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.2028-17.2017</ArticleId>
            <ArticleId IdType="pmc">PMC5777108</ArticleId>
            <ArticleId IdType="pubmed">29192126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brier M.R., Gordon B., Friedrichsen K., McCarthy J., Stern A., Christensen J., Owen C., Aldea P., Su Y., Hassenstab J., et al.  Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease. Sci. Transl. Med. 2016;8:338ra66. doi: 10.1126/scitranslmed.aaf2362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aaf2362</ArticleId>
            <ArticleId IdType="pmc">PMC5267531</ArticleId>
            <ArticleId IdType="pubmed">27169802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pontecorvo M.J., Devous M.D., Navitsky M., Lu M., Salloway S., Schaerf F.W., Jennings D., Arora A.K., McGeehan A., Lim N.C., et al.  Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain. 2017;140:748–763. doi: 10.1093/brain/aww334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/aww334</ArticleId>
            <ArticleId IdType="pmc">PMC5382945</ArticleId>
            <ArticleId IdType="pubmed">28077397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perneczky R., Wagenpfeil S., Komossa K., Grimmer T., Diehl J., Kurz A. Mapping scores onto stages: Mini-mental state examination and clinical dementia rating. Am. J. Geriatr. Psychiatry. 2006;14:139–144. doi: 10.1097/01.JGP.0000192478.82189.a8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.JGP.0000192478.82189.a8</ArticleId>
            <ArticleId IdType="pubmed">16473978</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
